Related Experiment Video

Updated: Jul 12, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Current treatment strategies in early stage Hodgkin's disease

Andreas Josting1, Volker Diehl

  • 1First Department of Internal Medicine, University Hospital Cologne, Joseph-Stelzmann-Str 9, 50924 Cologne, Germany. andreas.josting@uni-koeln.de

Current Treatment Options in Oncology
|August 29, 2003
PubMed

Insights

Treatment for Hodgkin's disease (HD) depends on stage. Early stage unfavorable HD, identified by risk factors, requires more aggressive treatment for better outcomes.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Medicine

Background:

  • Hodgkin's disease (HD) treatment is historically stage-dependent, with early stages (I, II, IIIA) and advanced stages (III with B symptoms, IV) having distinct therapeutic approaches.
  • The Ann Arbor classification (Cotsworth modification) is a standard for staging Hodgkin's disease.
  • Certain clinical risk factors in early-stage HD patients were associated with significantly poorer prognoses.

Purpose of the Study:

  • To define early stage unfavorable Hodgkin's disease based on clinical risk factors.
  • To establish the need for more aggressive treatment strategies for this specific patient subgroup.
  • To refine treatment protocols for Hodgkin's disease based on risk stratification.

Main Methods:

  • Retrospective analysis of clinical data for Hodgkin's disease patients.
  • Identification of key clinical risk factors associated with adverse outcomes in early-stage disease.
  • Comparison of treatment outcomes between different risk groups within early-stage Hodgkin's disease.

Main Results:

  • Early stage Hodgkin's disease patients with specific clinical risk factors demonstrated a significantly worse outcome compared to those without these factors.
  • These findings led to the classification of these patients as having 'early stage unfavorable' or 'intermediate stage' HD.
  • The identification of this subgroup necessitated a re-evaluation of standard treatment protocols.

Conclusions:

  • Risk stratification is crucial for optimizing Hodgkin's disease treatment.
  • Early stage unfavorable Hodgkin's disease requires a more aggressive therapeutic approach.
  • Further research into tailored treatment strategies for risk-stratified Hodgkin's disease patients is warranted.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...